![First Human Clinical Trial Finds CRISPR Gene-edited Cells Safe and Durable for Cancer Therapy | Technology Networks First Human Clinical Trial Finds CRISPR Gene-edited Cells Safe and Durable for Cancer Therapy | Technology Networks](https://assets.technologynetworks.com/production/dynamic/images/content/330353/first-human-clinical-trial-finds-gene-edited-cells-safe-and-durable-for-cancer-therapy-330353-480x270.jpg?cb=10577280)
First Human Clinical Trial Finds CRISPR Gene-edited Cells Safe and Durable for Cancer Therapy | Technology Networks
![The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancer | Signal Transduction and Targeted Therapy The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancer | Signal Transduction and Targeted Therapy](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41392-020-00283-8/MediaObjects/41392_2020_283_Fig1_HTML.png)
The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancer | Signal Transduction and Targeted Therapy
![Intellia's early CRISPR trial data validate a drug pipeline and the gene-editing field - MedCity News Intellia's early CRISPR trial data validate a drug pipeline and the gene-editing field - MedCity News](https://medcitynews.com/uploads/2021/06/intellia-lnp-body-graphic-v3-6-17-21.jpg)
Intellia's early CRISPR trial data validate a drug pipeline and the gene-editing field - MedCity News
CRISPR-Edited Immune Cells Can Survive and Thrive After Infusion into Cancer Patients - Penn Medicine
![UC Consortium Launches First Clinical Trial Using CRISPR to Correct Gene Defect That Causes Sickle Cell Disease | UC San Francisco UC Consortium Launches First Clinical Trial Using CRISPR to Correct Gene Defect That Causes Sickle Cell Disease | UC San Francisco](https://www.ucsf.edu/sites/default/files/styles/article_feature_banner__image/public/2021-03/Sickle-Cell-1920x1000.jpg)